Vernon Johnson
Child & Adolescent Psychiatry · Sherman, TXNPI 1639228992
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 315 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Among child & adolescent psychiatry clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 315 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$702
- AbbVie$571
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$556
- E.r. Squibb & Sons, L.L.C.$455
- Ironshore Pharmaceuticals Inc.$364
- Sunovion Pharmaceuticals Inc.$340
- plus $3K from 29 others
What the payments were for
- Food & beverage$5,536100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 46 | $702 |
| AbbVie(2 entities) | 70 | $571 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $556 |
| E.r. Squibb & Sons, L.L.C. | 17 | $455 |
| Ironshore Pharmaceuticals Inc. | 13 | $364 |
| Sunovion Pharmaceuticals Inc. | 23 | $340 |
| Corium, LLC | 10 | $283 |
| Supernus Pharmaceuticals, Inc. | 14 | $256 |
| Tris Pharma Inc | 15 | $253 |
| Neurocrine Biosciences, Inc. | 7 | $245 |
| Johnson & Johnson | 6 | $184 |
| Noven Therapeutics, LLC | 7 | $128 |
| Teva Pharmaceuticals USA, Inc. | 5 | $112 |
| Avanir Pharmaceuticals, Inc. | 8 | $109 |
| Eisai Inc. | 5 | $91 |
| Axsome Therapeutics, Inc. | 4 | $79 |
| Shire North American Group Inc | 6 | $75 |
| Adlon Therapeutics L.p. | 5 | $74 |
| Livanova USA, Inc. | 4 | $74 |
| Brainsway USA Inc | 1 | $65 |
| Neos Therapeutics, LP | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $55 |
| Almatica Pharma LLC | 3 | $54 |
| Lundbeck LLC | 3 | $53 |
| Alkermes, Inc. | 2 | $46 |
| Arbor Pharmaceuticals, Inc. | 3 | $41 |
| Bausch Health US, LLC | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| GE HealthCare | 2 | $36 |
| Tempus AI, Inc | 1 | $26 |
| Neuronetics, Inc. | 1 | $19 |
| Indivior Inc. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| OWP Pharmaceuticals, Inc. | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,541 in reported general payments places this provider in the 90th percentile of 301 child & adolescent psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 26 | $126,210 |
| VraylarCariprazine Hcl | 18 | $26,468 |
| Paliperidone ErPaliperidone | 35 | $14,004 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 107 | $7,962 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 154 | $5,967 |
| Asenapine Maleate | 21 | $3,440 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 75 | $2,697 |
| Doxepin Hcl | 30 | $1,347 |
| Clonazepam | 130 | $1,330 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 24 | $1,069 |
| Bupropion XlBupropion Hcl | 77 | $1,065 |
| Oxcarbazepine | 26 | $1,028 |
| Alprazolam | 182 | $986 |
| Mirtazapine | 35 | $877 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 36 | $829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $112 | $126,21026 claims |
| AbbVieVraylar | $571 | $26,46818 claims |
| Almatica Pharma LLCSertraline Hcl | $54 | $13129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 301 child & adolescent psychiatry providers in Texas.
Other child & adolescent psychiatry in Sherman
- Alain KaticBellaire$106K
- Steven PliszkaSan Antonio$59K
- Mary Garcia HolguinSan Antonio$24K
- John SteffekSpring$14K
- Robert MosquedaEdinburg$13K
- Gloria BrunGreenville$10K
- Mudassar TariqSugar Land$9K
- Charles PryzantDallas$9K
- Mehvesh AfrinaPlano$8K
- Kishore SunkaraHurst$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.